Results 121 to 130 of about 22,676 (187)

TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches. [PDF]

Front Oncol
Deshpande S, Li WF, Song J, Forsberg M, Cerchione C, Martinelli G, Konopleva M.   +6 more
europepmc   +1 more source

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation [PDF]

, 2017

core   +1 more source

Molecularly targeted therapy and immunotherapy in leukemias. [PDF]

J Hematol Oncol
Cousin E, Picard A, Oundjian M, Tardif N, Quemener A, Rio AG, Galibert MD, Gandemer V, Mazurier F.   +8 more
europepmc   +1 more source

XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]

Cell Commun Signal
Xu TT, Cai MC, Cheng S, Huang YH, Zhang QQ, Xu PP, Wang L, Qiu YR, Zhao WL.   +8 more
europepmc   +1 more source

Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold? [PDF]

Cancers (Basel)
Schreiber J, Hopfinger G, Gleixner KV.
europepmc   +1 more source

Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress. [PDF]

Blood Adv
Mayerhofer C, Crompton E, Mayerhofer E, Kristiansen T, Fukushima T, Keyes S, Sharda A, Li D, Da Silva C, Shrestha D, Kiem A, Feuchtinger T, Scadden DT, Miller PG.   +13 more
europepmc   +1 more source

Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. [PDF]

Am J Hematol
Konopleva M, DiNardo CD, Sun Y, Jung P, Loghavi S, Potluri J, Dail M, Chyla B, Pollyea DA.   +8 more
europepmc   +1 more source

Azacitidine as maintenance therapy in pediatric <i>de novo</i> acute myeloid leukemia. [PDF]

Front Immunol
Wu C, Cai C, Li M, Li N, Zheng Y, Zheng H.   +5 more
europepmc   +1 more source

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes. [PDF]

Blood Adv
Sallman DA, McLemore AF, Komrokji R, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala J, Yoder SJ, Perez L, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A.   +15 more
europepmc   +1 more source

5-Azacitidine Partially Resets the Subcellular Localization of YAP in Human Bone Marrow-Derived Mesenchymal Stem Cells. [PDF]

Cells
Takayama H, Kishi H, Kobashi G.
europepmc   +1 more source